I'll bite on this one, because the thread drifted toward MT2 and that is where the useful distinction actually lives.
PT-141 and MT2 are not the same tool wearing different labels. Bremelanotide came out of work that trimmed melanotan II down and pushed it toward receptor selectivity, and the entire point of that effort was to retain the libido effect while shedding some of the broader activity. That distinction is the reason one of them went through clinical development and ended up as a prescription product for hypoactive sexual desire disorder in premenopausal women, while the other stayed a research peptide sold in vials.
What the approval package documented is worth knowing before anyone treats this as a casual experiment. Nausea is the dominant complaint and it shaped the dosing guidance that came with the product. Transient blood pressure elevation and changes in heart rate were significant enough that cardiovascular cautions appear on the label, and earlier formulations in this family got shelved partly because of how they behaved on blood pressure. This is a drug with a real hemodynamic footprint, not a harmless little peptide.
MT2 is a different proposition entirely. It is a non-selective melanocortin agonist, so it engages more receptors than bremelanotide does, which is why it produces both the tanning and the libido effects and also why its side effect profile is wider. Reports of new moles appearing and existing ones darkening during use show up often enough in dermatology literature and in user accounts that they deserve to be taken seriously, and nobody selling it is monitoring your skin for you.
The part of the thread I would push back on is the framing. Female desire is multifactorial. Hormonal status, thyroid function, other medications, sleep, mood and relationship dynamics all sit inside that picture, and a melanocortin agonist addresses one narrow slice of it. If the original issue was genuine, the approved product exists as a prescription and there is a legitimate clinical route to it, which incidentally also solves the supply problem that started this thread. Working around a shortage by buying a gray market vial trades a logistics inconvenience for an unknown compound of unknown purity and no oversight.
